Medical Cannabis for Chronic Pain: Promise, Pharmacology, and Persistent Gaps
This 2025 medical cannabis chronic pain review examines the pharmacology and clinical evidence for cannabinoids in pain management. While promising, significant gaps remain in standardized dosing and long-term safety data. The review highlights the need…
Edible Brands Launches First THC Retail Store Along Atlanta Beltline
Retail THC products regulation is evolving as Edible Brands opens its first THC retail store in Atlanta. This development highlights the challenges clinicians face with hemp-derived THC limits. Understanding cannabis edible dosing is essential for…
Jazz Pharmaceuticals Presents New Data on Epidiolex® and Idiopathic Hypersomnia
Idiopathic hypersomnia cannabidiol research is advancing with new clinical trial data from Jazz Pharmaceuticals. This research highlights mood improvements and safety profiles of Epidiolex® in patients. Clinicians can use these insights to inform…
This is brazillian weed
When your patient’s strain provenance is somehow more mysterious than their symptom timeline. At least the pharmacology doesn’t require a passport. Via r/trees Further Reading CED Clinic BlogMusshoff and Madea – 2006 – Review of…
FloraWorks Announces TruCBN(TM) Readiness for CMS Substance Access Program
FloraWorks has announced TruCBN(TM) readiness for CMS Substance Access, highlighting CBN clinical validation pathways. This development signals potential regulatory progress for cannabinoid products. Clinicians should monitor emerging evidence on CBN…
Artifacts recovered from WWII ‘hell ship’ wreck as US searches for fallen in Subic – ABS-CBN
Artifacts recovered wwii hell ship wreck highlight significant historical findings in Subic Bay. This discovery aids the US search for fallen WWII soldiers. Clinicians and historians alike find this development notable.
CBD for Calm: How to Use It in Real Life (Timing, Format & What to Expect)
CBD dosing anxiety treatment is a common patient inquiry in cannabis medicine. Clear, evidence-based guidance helps clinicians counsel patients effectively. Understanding dosing protocols and realistic expectations is key to using CBD for calm.
SYNBIOTIC Enters Spring 2026 with Operational Progress and Regulatory Momentum
SYNBIOTIC reports notable 2026 cannabis regulatory momentum alongside operational progress this spring. This momentum reflects ongoing developments in cannabis industry regulations. Clinicians should monitor these regulatory updates for their potential…
Medicinal Cannabis Demand for Mental Health Soars, Evidence Lags – Monash Lens
Medicinal cannabis mental health demand is rapidly increasing, especially for anxiety and PTSD. However, clinical evidence supporting its use remains limited. This gap creates challenges for healthcare providers balancing patient needs and treatment…
New York Approves Cannabis for Anxiety: Clinical Evidence Review
Cannabis for anxiety disorders is a growing topic in medical cannabis policy. Current clinical evidence remains mixed, with some studies showing limited benefits. Patients and clinicians should carefully consider the risks and monitor outcomes.
